Dhampur Bio Organics (DBOL.NS) Earnings Analysis
Dhampur Bio Organics (DBOL.NS) next reports earnings on 2026-07-29, consensus EPS 1.9 INR. Last quarter (2026-07-14) it beat with EPS 5.59 INR vs 1.2 INR est (+365.8%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E 7.93.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does DBOL.NS next report earnings?
| Next earnings date | 2026-07-29 |
|---|---|
| Consensus EPS estimate | 1.9 INR |
| Revenue estimate | 5.99B |
DBOL.NS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-07-14 | 5.59 INR | 1.2 INR | +365.8% | Beat |
| 2026-05-30 | 7.01 INR | n/a | n/a | n/a |
| 2025-11-13 | -2.41 INR | n/a | n/a | n/a |
| 2025-07-28 | -3.31 INR | n/a | n/a | n/a |
| 2025-05-02 | 6.75 INR | n/a | n/a | n/a |
| 2024-11-04 | -3.52 INR | n/a | n/a | n/a |
| 2024-07-25 | 0.0181 INR | n/a | n/a | n/a |
Beat rate: 1/1 (100%) over reported quarters with consensus data.
DBOL.NS valuation and analyst view
| Trailing P/E | 7.93 |
|---|---|
| Trailing EPS | 5.081 INR |
| Price / book | 0.65 |
| Dividend yield | 1.49% |
| Market cap | 6.82B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Dhampur Bio Organics (DBOL.NS)'s next earnings date?
Dhampur Bio Organics is next scheduled to report on 2026-07-29, with a consensus EPS estimate of 1.9 INR and revenue estimate of 5.99B.
Did DBOL.NS beat earnings last quarter?
In its 2026-07-14 report, DBOL.NS posted EPS of 5.59 INR versus a 1.2 INR estimate — a beat of 365.8%.
What is DBOL.NS's earnings track record?
Over the last 1 reported quarters with consensus data, DBOL.NS beat estimates 1 times (100%).
What is DBOL.NS's current P/E ratio and EPS?
DBOL.NS trades at a trailing P/E of 7.93 on trailing EPS of 5.0814282537443045 INR.
What do analysts rate DBOL.NS?
DBOL.NS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.